Structure Therapeutics
Xianqiang Song has extensive experience in the field of structural biology. Xianqiang is currently the Director of Structural Biology at Structure Therapeutics, a position they have held since August 2022. Prior to this, they worked as the Associate Director of Structural Biology at Basecamp Bio from April 2021 to July 2022.
Before joining Basecamp Bio, Xianqiang served as a Scientist at Amgen's Asia R&D Center. In this role, they led the structural biology group, focusing on understanding the fundamental mechanism of therapeutic targets and facilitating drug discovery. Their responsibilities ranged from construct design and expression to purification and structure determination using both x-ray crystallography and cryo-EM. Xianqiang held this position from April 2019 to April 2021.
Xianqiang's journey in structural biology began at OHSU | Oregon Health & Science University, where they worked as a Post Doctoral Fellow from January 2014 to April 2018.
Xianqiang Song completed a Bachelor of Science (BS) degree in Biotechnology from UESTC between 2004 and 2008. Following this, Xianqiang went on to pursue a Doctor of Philosophy (Ph.D.) in Structural Biology at the University of Chinese Academy of Sciences, which was completed from 2008 to 2013.
This person is not in any offices
Structure Therapeutics
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.